Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide, an ...

By Chioma Obinna Scientists have called on pharmacists to prioritise research and ethical practice over immediate financial ...

The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development.

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in people with obesity.

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

FDA-approved drugs are also often patented and subject to various laws regarding exclusivity for a given manufacturer. At the ...

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

The final analysis showed similar overall survival, progression-free survival, and objective response rates, with no new safety signals identified compared with the primary analysis.

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...